Floatz logo

METHOTREXATE

Recurrent Adult T-cell Leukemia/Lymphoma

Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Recurrent Adult T-cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 2BBB
Fludarabine
John Reneau
Phase 2BBB
Cyclophosphamide
John Reneau
Phase 4BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Northwestern University
Phase 2BBB

View all 50 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →